Table 2 Prevalence of MTHFR genotypes in pSS non-MALT and healthy control groups, adjusted by gender and age.

From: MTHFR gene variants and non-MALT lymphoma development in primary Sjogren’s syndrome

SNPs MTHFR Genotype HAPMAP Database (%) pSS non-MALT (n = 19) n (%) Healthy controls (n = 600) n (%) OR codominant model [95%CI] p-value OR dominant model [95%CI] p-value OR recessive model [95%CI] p-value OR overdominant model [95%CI] p-value OR log-additive model [95%CI] p-value
      CC vs CT vs TT   (CT-TT) vs CC   TT vs (CC-CT)   CT vs (CC-TT)    
  CC 46.9 4 (21.1) 235 (39.2) 1.00 0.18 2.34 [0.76-7.18] 0.11 2.23 [0.76-6.52] 0.17 1.22 [0.49-3.08] 0.67 1.86 [0.96-3.64] 0.07
c. 677C>T CT 44.2 10 (52.6) 291 (48.5) 2.02 [0.62-6.55]
  TT 8.8 5 (26.3) 74 (12.3) 3.50 [0.89-13.65]
      AA vs AC vs CC   (AC-CC) vs AA   CC vs (AA-AC)   AC vs (AA-CC)    
  AA 43.4 15 (79.0) 273 (45.5) 1.00 0.01 0.25 [0.08-0.78] 0.008 0.00 [0.00-NA] 0.06 0.37 [0.12-1.14] 0.06 0.27 [0.09-0.77] 0.004
c. 1298A>C AC 45.1 4 (21.1) 266 (44.3) 0.31 [0.10-0.95]
  CC 11.5 0 (0.0) 61 (10.2) 0.00 [0.00-NA]
  1. Genotypes, OR and p-value for the five genetic models (codominant, dominant, recessive, overdominant and additive) were estimated with SNPstats software (statistically significant if p < 0.05).
  2. MTHFR: methylene tetrahydrofolate reductase, pSS: primary Sjogren’s syndrome, MALT: mucosa-associated lymphoid tissue, OR: odds ratio, SNP: single nucleotide polymorphism, vs: versus, HAPMAP: haplotype map.